Exscientia PLC

NASDAQ:EXAIUnited States

Exscientia PLC is a drug design and development company. The Company combines precision design with integrated experimentation to invent and develop drugs. It uses artificial intelligence (AI) in drug discovery to progress AI-designed small molecules into a clinical setting. It uses the patient's tissue data to define optimal profiles for research, improve experimental assessment during design and improve outcomes in a medical setting. It has developed an internal pipeline focused on oncology, while its partnered pipeline extends to various other therapeutic areas. It combines genetic data and global literature in machine learning models to anticipate and confirm disease-target associations. The Company's experimental platform records responses in real patient samples allowing it to generate high-precision views of potential patient response. Its product pipeline consists of GTAEXS617, EXS4318, EXS74539, and EXS73565.

Contact Information

Headquarters

The Schrodinger Building Oxford Science ParkOXFORD, United Kingdom OX4 4GE

Phone

186-581-8941

Fax

---

Executives

Non-Executive Independent Chairman of the Board

Elizabeth Crain

Chief Executive Officer, Director

David Hallett

Chief Financial and Strategy Officer, Director

Ben Taylor

Chief Technology Officer

John Overington

Interim Chief Medical Officer

Maria-louise Fjaellskog